4293

This is one of the first longevity transactions to be completed in continental Europe and confirms SCOR’s pioneering role in this emerging and important market.

SCOR delivers a strong performance for the first nine months of 2013, recording net income of EUR 302 million.

SCOR delivers a strong performance for the first nine months of 2013, recording net income of EUR 302 million.

Standard & Poor’s has raised the outlook on the “A+” rating of SCOR SE and its main subsidiaries to “positive” as, according to S&P’s statement, “capital and earnings expected to rise due to very strong ERM”.

The aims of this brochure are to provide the reader with a simple introduction to genes and genetic processes in humans and an insight as to how this rapidly developing field of science could impact on the insurance i

The aims of this brochure are to provide the reader with a simple introduction to genes and genetic processes in humans and an insight as to how this rapidly developing field of science could impact on the insurance i

The aims of this brochure are to provide the reader with a simple introduction to genes and genetic processes in humans and an insight as to how this rapidly developing field of science could impact on the insurance i

Winner of the Actuarial Award in Germany, 2013

Winner of the Actuarial Award in Germany, 2013

Winner of the Actuarial Award in Germany, 2013